Deal Tracker · Countries

United States pharma licensing deals

9 licensing deals involving United States tracked by EPT (2021–2026). Most active: Gilead Sciences, Hikma Pharmaceuticals, Bio-Thera Solutions & Dr. Reddy's Laboratories. Latest: Gilead Sciences → Dr. Reddy's Laboratories (Licensing, 16 Nov 2026).

9
deals tracked
7
announced in 2026
$259m
disclosed value (1 deal)
100%
licensing, the top deal type
  • EPT has tracked 9 United States pharma licensing deals (2021–2026), 7 of them announced in 2026.
  • The countries that appear most often are Saudi Arabia (2), China (1), Egypt (1) & India (1).
  • Values were disclosed for 1 of 9 deals, totalling $259m; the largest is Ocugen → Roots Pharmaceutical ($259m, 14 Oct 2026).
  • The most active companies: Gilead Sciences (3) & Hikma Pharmaceuticals (2).

Most active companies

Gilead Sciences (3) · Hikma Pharmaceuticals (2)

Countries involved

Saudi Arabia (2) · China (1) · Egypt (1) · India (1) · Kuwait (1) · Pakistan (1)

Largest disclosed deals

Questions

How many United States pharma licensing deals has EPT tracked?
9 as of 16 Nov 2026, covering 2021–2026; 7 were announced in 2026. The most recent is Gilead Sciences → Dr. Reddy's Laboratories (Licensing, 16 Nov 2026).
Which companies are most active in United States pharma licensing deals?
Gilead Sciences (3 deals), Hikma Pharmaceuticals (2 deals).
What is the largest disclosed United States pharma licensing deal?
Ocugen → Roots Pharmaceutical: $259m (Licensing, 14 Oct 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)